Join to View Full Profile
44 Binney StDanafarber Cancer InstituteBoston, MA 02115
Phone+1 617-632-6184
Fax+1 617-632-5370
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pankaj Bhargava, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, California, and District of Columbia.
Education & Training
- MedStart Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
- Maimonides Medical CenterResidency, Internal Medicine, 1992 - 1995
- Delhi University College of Medical SciencesClass of 1991
Certifications & Licensure
- DC State Medical License 1996 - Present
- CA State Medical License 2007 - 2026
- MA State Medical License 2000 - 2020
- VA State Medical License 1996 - 2018
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsMatrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.Vitali Lounev, Jay C Groppe, Niambi Brewer, Kelly L Wentworth, Victoria Smith
Journal of Bone and Mineral Research. 2024-05-02 - 2 citationsEfficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.Nadine Kutsch, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow
Hemasphere. 2022-06-01 - 7 citationsEfficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen
Hemasphere. 2022-04-01
Press Mentions
- MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive PartnerApril 13th, 2021
- Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)May 13th, 2016
- Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical OfficerApril 2nd, 2014